Last reviewed · How we verify
GST-HG121 tablets — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GST-HG121 tablets (GST-HG121 tablets) — Fujian Akeylink Biotechnology Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GST-HG121 tablets TARGET | GST-HG121 tablets | Fujian Akeylink Biotechnology Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GST-HG121 tablets CI watch — RSS
- GST-HG121 tablets CI watch — Atom
- GST-HG121 tablets CI watch — JSON
- GST-HG121 tablets alone — RSS
Cite this brief
Drug Landscape (2026). GST-HG121 tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/gst-hg121-tablets. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing